Summaries of the Section H (HML) update
Each month we issue a summary of the HML update. The table on this page gives a preview of the upcoming changes.
The table on this page gives a preview of the upcoming changes that will be announced in next month’s Section H of the Pharmaceutical Schedule.
The changes will be published in the Online HML(external link) around the 23rd of this month and are effective from next month.
For any questions about these listing changes or the Pharmaceutical Schedule in general, email us at enquiry@pharmac.govt.nz.
18 September 2025 - preview of changes for October 2025
|
Pharmaceutical |
Change |
|---|---|
|
Amino acid formula (without isoleucine, leucine and valine) (MSUD Lophlex LQ 20) liquid (juicy berries), 20 g protein, 12.63 g carbohydrate and 0.46 g fat per 125 ml pouch |
new listing (p’code 2711451) |
|
Amino acid formula (without isoleucine, leucine and valine) (MSUD Lophlex LQ 20) liquid (juicy berries), 20 g protein, 8.8 g carbohydrate, 0.44 g fat and 0.5 g fibre per 125 ml pouch |
to be delisted 1 March 2026 |
|
Amino acid formula (without methionine) (HCU Lophlex LQ) liquid (juicy berries), 20 g protein, 12.63 g carbohydrate and 0.46 g fat per 125 ml |
new listing (p’code 2711478) |
|
Amino acid formula (without methionine) (HCU Lophlex LQ) liquid (juicy berries), 20 g protein, 9.3 g carbohydrate, 0.44 g fat and 0.44 g fibre per 125 ml bottle |
to be delisted 1 March 2026 |
|
Ascorbic acid (Cvite) tab 100 mg |
price increase and addition of PSS |
|
Caspofungin (Alchemy Caspofungin) inj 50 mg and 70 mg vial |
addition of PSS |
|
Chloramphenicol eye drops 0.5%, 10 ml |
Brand change
|
|
Clindamycin inj 150 mg per ml, 4 ml ampoule |
Brand change
|
|
Dexamethasone phosphate inj 4 mg per ml, 1 ml and 2 ml ampoule |
Brand change Dexamethasone Medsurge – new listing and addition of PSS
Hameln to be delisted 1 March 2026 |
|
Dipyridamole (Pytazen SR) tab long-acting 150 mg |
to be delisted 1 January 2026 |
|
Efavirenz with emtricitabine and tenofovir disoproxil (Triovir) tab 600 mg with emtricitabine 200 mg and tenofovir disoproxil 245 mg (300 mg as a fumarate) |
to be delisted 1 January 2026 |
|
Ethinyloestradiol with norethisterone (Alyacen) tab 35 mcg with norethisterone 1 mg and 7 inert tab |
to be delisted 1 January 2026 |
|
Fluoxetine hydrochloride (Fluox) tab dispersible 20 mg, scored |
price decrease and addition of PSS |
|
Fluoxetine hydrochloride (Arrow-Fluoxetine) cap 20 mg |
price increase and addition of PSS |
|
Lenalidomide (Viatris) (Lenalidomide Viatris) cap 5 mg |
Pharmacode 2673525 to be delisted 1 January 2026 |
|
Lidocaine [lignocaine] (LMX4) crm 4%, 5 g and 30 g |
price increase |
|
Lisinopril (Teva Lisinopril) tab 5 mg, 10 mg and 20 mg |
price increase and addition of PSS |
|
Long-chain triglyceride supplement (Calogen (neutral)) liquid 50 g fat per 100 ml, bottle, 500 ml |
to be delisted 1 March 2026 |
|
Macrogol 3350 with potassium chloride, sodium bicarbonate and sodium chloride (APO Health Macrogol) powder for oral soln 13.125 g with potassium chloride 46.6 mg, sodium bicarbonate 178.5 mg and sodium chloride 350.7 mg |
to be delisted 1 January 2026 |
|
Mesalazine tab EC 400 mg (Octasa) and tab 800 mg (Asacol) |
new listing
|
|
Nirmatrelvir with ritonavir (Paxlovid) tab 150 mg with ritonavir 100 mg |
new Pharmacode listing (p’code 2711613) |
|
Nirmatrelvir with ritonavir (Paxlovid (Pharmac)) tab 150 mg with ritonavir 100 mg |
amended brand name and Pharmacode 2635143 to be delisted 1 December 2025 |
|
Norethisterone (Norethinderone – CDC) tab 350 mcg |
to be delisted 1 January 2026 |
|
Olopatadine (Olopatadine Teva) eye drops 0.1%, 5 ml |
price increase and addition of PSS |
|
Oral feed (Ensure (Chocolate) and (Vanilla)) powder 15.9 g protein, 57.4 g carbohydrate and 14 g fat per 100 g, can, 850 g |
price increase |
|
Oxytocin (Oxytocin BNM) inj 5 iu and 10 iu per ml, 1 ml ampoule |
price increase and addition of PSS |
|
Paroxetine (Paxtine) tab 20 mg |
to be delisted 1 March 2026 |
|
Podophyllotoxin (Condyline) soln 0.5%, 3.5 ml |
new listing (p’code 2714205) |
|
Raloxifene (Evista) tab 60 mg |
to be delisted 1 April 2026 |
|
Rocuronium bromide (Medsurge) inj 10 mg per ml, 5 ml vial |
new listing and addition of PSS (p’code 2690500) |
|
Rocuronium bromide (Hameln) inj 10 mg per ml, 5 ml ampoule |
to be delisted 1 May 2026 |
|
Spironolactone (Spiractin) tab 25 mg and 100 mg |
price increase and addition of PSS |
|
Sodium cromoglicate (Allerfix) eye drops 2%, 10 ml |
price increase and addition of PSS |
|
Sodium hyaluronate [hyaluronic acid] inj 18 mg per ml, 0.85 ml syringe (Healon GV Pro), inj 23 mg per ml, 0.6 ml syringe (Healon 5) and inj 10 mg per ml, 0.85 ml syringe (Healon) |
addition of PSS |
|
Sunitinib cap 12.5 mg and 25 mg |
Brand change Sunitinib Rex – new listing and addition of PSS
Sunitinib Pfizer to be delisted 1 March 2026 |
|
Venlafaxine (Enlafax XR) cap 37.5 mg and 75 mg |
new Pharmacode listing
|
|
Zinc sulphate (Zincaps) cap 137.4 mg (50 mg |
new Pharmacode listing (p’code 2714019) |